Status:
COMPLETED
Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.
Lead Sponsor:
Hospital Universitari Son Dureta
Collaborating Sponsors:
Espen
This research prize was funded by Nestle Nutrition Institute and by Fresenius Kabi.
Conditions:
Moderate to Severe Trauma, as Defined by an
Injury Severity Score (ISS) > 12 Points Were Included in the Study.
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Glutamine is the most abundant nonessential amino acid in the human body. Besides its role as a constituent of proteins and its importance in amino acid transamination, glutamine may modulate immune c...
Detailed Description
Objective: To evaluate whether glutamine supplementation alters the expression and functionality of TLR2 and TLR4 in circulating monocytes of trauma patients admitted to the ICU. Specifically the next...
Eligibility Criteria
Inclusion
- Age between 18 and 75 years (inclusive).
- Moderate to severe trauma, as defined by an Injury Severity Score (ISS) \> 12 points were included in the study
- Traumatic patients who required total parenteral nutrition
Exclusion
- Patients who were under 17 and over 76 years of age,
- Patients whose life expectancy was less than 5 days
- Patientes allergic to glutamine.
- Patients with any basic pathology included any serious immune system condition (diabetes, HIV, lupus, etc.) or who, in their long-term treatment prior to admission to ICU, received corticoids or any other immunosuppressant medication.
- Pregnant women.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT01250080
Start Date
January 1 2007
End Date
September 1 2008
Last Update
November 30 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intensive Care Unit. Hospital Universitario Son Dureta
Palma Mallorca, Balearic Islands, Spain, 07014